These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37796543)

  • 1. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
    Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
    J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Pyrrolo[2,3-
    Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
    J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
    Jiang XC; Tu FH; Wei LY; Wang BZ; Yuan H; Yuan JM; Rao Y; Huang SL; Li QJ; Ou TM; Wang HG; Tan JH; Chen SB; Huang ZS
    J Med Chem; 2022 Sep; 65(18):12346-12366. PubMed ID: 36053318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer.
    Jia S; Jia Y; Liang S; Wu L
    Bioorg Med Chem; 2024 Aug; 110():117827. PubMed ID: 38964169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Thieno[2,3-
    Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
    J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
    Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
    Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer.
    Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
    Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
    Zhang J; Tang P; Zou L; Zhang J; Chen J; Yang C; He G; Liu B; Liu J; Chiang CM; Wang G; Ye T; Ouyang L
    J Med Chem; 2021 Dec; 64(24):18025-18053. PubMed ID: 34908415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
    Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
    Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
    Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
    Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins.
    Zhou YD; Li J; Du L; Mahdi F; Le TP; Chen WL; Swanson SM; Watabe K; Nagle DG
    Mar Drugs; 2018 Nov; 16(11):. PubMed ID: 30423844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.
    Chuang YF; Huang SW; Hsu YF; Yu MC; Ou G; Huang WJ; Hsu MJ
    Br J Pharmacol; 2017 Sep; 174(17):2941-2961. PubMed ID: 28646512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.